Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort (2024)
- Authors:
- Autor USP: PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1002/jha2.835
- Subjects: ESTUDOS DE COORTES; SISTEMA IMUNE; LINFOMA; INFLAMAÇÃO; BRASIL
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
VARGAS, Juliano Cordova et al. Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort. EJHAEM, v. 5, n. 1, p. 147-152, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/76824. Acesso em: 26 dez. 2025. -
APA
Vargas, J. C., Cecyn, K. Z., Marques, M. de O., Pereira, J., Braga, W. M. T., Hamerschlak, N., et al. (2024). Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort. EJHAEM, 5( 1), 147-152. doi:10.1002/jha2.835 -
NLM
Vargas JC, Cecyn KZ, Marques M de O, Pereira J, Braga WMT, Hamerschlak N, Tabacof J, Liz CD de, Abdo A, Ferreira PRA. Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort [Internet]. EJHAEM. 2024 ; 5( 1): 147-152.[citado 2025 dez. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76824 -
Vancouver
Vargas JC, Cecyn KZ, Marques M de O, Pereira J, Braga WMT, Hamerschlak N, Tabacof J, Liz CD de, Abdo A, Ferreira PRA. Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort [Internet]. EJHAEM. 2024 ; 5( 1): 147-152.[citado 2025 dez. 26 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76824 - Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
- Comparison between R-CHOP vs R-CHOP plus etoposide in untreated patients with primary mediastinal B-cell lymphoma: Preliminary findings
- Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)
- Follicular lymphoma: refining prognostic models and impact of pod-24 in clinical outcomes
Informações sobre o DOI: 10.1002/jha2.835 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
